SCHEDULE: T. Rowe Price Discloses Select Medical Holdings Stake

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting beneficial ownership of 0.1% of Select Medical Holdings Corp. common stock as of March 31, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed an amendment (Amendment No. 13) to its Schedule 13G filing.
• The filing pertains to Select Medical Holdings Corp. common stock.
• As of March 31, 2026, T. Rowe Price Associates, Inc. beneficially owns 165,144 shares of common stock.
• This represents 0.1% of the class of securities.
• The reporting entity, T. Rowe Price Associates, Inc., is based in Maryland and is classified as an investment adviser.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of a minor ownership stake by an institutional investor, with a specific denial of beneficial ownership, which doesn't provide new operational or strategic insights into the company itself.

Positives

• T. Rowe Price Associates, Inc. maintains a beneficial ownership stake in Select Medical Holdings Corp., indicating continued investment interest.
• The filing confirms that the securities are held in the ordinary course of business, suggesting standard investment practices.

Negatives

• The reported beneficial ownership is a small percentage (0.1%) of the total class of securities, indicating a minor stake.
• T. Rowe Price Associates, Inc. expressly denies beneficial ownership, stating the filing should not be construed as an admission of such.

Risks

• The filing does not explicitly detail risks associated with Select Medical Holdings Corp. itself, but rather focuses on the reporting entity's investment status.
• The denial of beneficial ownership by T. Rowe Price Associates, Inc. could imply a passive investment role or a specific regulatory interpretation, which might be a point of scrutiny for investors.

Future Outlook

The filing does not contain forward-looking statements or guidance from Select Medical Holdings Corp. It is a disclosure of beneficial ownership by an investment entity.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates T. Rowe Price Associates, Inc.'s passive investment in Select Medical Holdings Corp., a healthcare provider, and its adherence to regulatory reporting requirements.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, though the small percentage and denial of beneficial ownership may limit its direct impact on share price perception.
• Management: The filing confirms T. Rowe Price Associates, Inc.'s passive investment approach, which does not indicate any intent to influence management decisions.
• Regulators: The filing demonstrates compliance with SEC reporting requirements for beneficial ownership.

Next Steps

• T. Rowe Price Associates, Inc. will continue to hold its shares in Select Medical Holdings Corp. in the ordinary course of business.
• Future filings will be made if ownership levels change significantly according to SEC regulations.

Key Dates

Keywords

Select Medical Holdings Corp, Schedule 13G, T. Rowe Price Associates, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Amendment